Preface

 

In light of COVID-19 there have been mitigation strategies implemented either nationally or within local hospitals in relation to the management of patients that are high risk such as those receiving cancer chemotherapy. We developed a survey to capture the views of healthcare professionals currently delivering cancer care.

The survey is developed by an international interdisciplinary team with researchers from the Rapid Research, Evaluation and Appraisal Lab (RREAL), University College London and University College London NHS Foundation Trust. To obtain more information about this collaboration please contact Dr Pinkie Chambers (p.chambers@ucl.ac.uk).

Research findings will enable a better understanding of the current global measures which will be important for future virus outbreaks should they ever occur.

 

1. Who has given ethical approval for this study?

This study was approved by the University College London (UCL) Research Ethics Committee (REC). REC number 6862/005.

 

2. Why have I been asked to take part?

We wish to capture a wide range of views from the people in charge of designing, implementing and interacting with the delivery of cancer care in the current pandemic climate. We believe you have a valuable perspective. 

 

3. What does taking part involve?

The survey will include questions about your current role and your experience of current cancer care policy and implementation.

 

4. Do I have to take part? 

No, it is up to you to decide whether or not to take part. If you decide to take part and click on the link to complete the survey, this will be taken as consent.

 

5. Is what I say confidential?

Yes, we will not inform anyone outside the research team that you have participated in the study. All information will be stored securely and will only be accessed by members of the research team. Your data will be archived securely for 20 years after the study's completion, before its eventual destruction. 

 

6. What if I change my mind?

You are free to withdraw from the survey at any time. Even if you start the survey, you can stop it at any point if you wish to.

 

7. What are the risks of taking part?

Helping us with this study will take up a little of your time. If you feel uncomfortable discussing any aspect of this study, you can withdraw from the survey at any time. You can also contact the study team to discuss any concerns you have before or after agreeing to take part.

 

8. What are the benefits of taking part?

There may be limited personal benefits emerging from the study, but the study aims to disseminate how countries around the world are managing patients that would normally have received systemic anti-cancer therapy. This will be important for future virus outbreaks if they should ever occur. The final results from the study will be shared across relevant networks and will be made available on the RREAL website. 

 

9. How will information be stored?

UCL is the sponsor for this study. We will be using information from you in order to undertake this study and will act as the data controller for this study. This means that we are responsible for looking after your information and using it properly. UCL will keep the information collected for this study for 20 years after the study has finished. Your rights to access, change or move your information are limited, as we need to manage this information in specific ways in order for research to be reliable and accurate. If you withdraw from the study, we will keep the information that we have already obtained. To safeguard your rights, we will use the minimum personally identifiable information possible. You can find out more about how we use the information collected for this study by contacting the research team using the contact details listed below.

 

10. What will happen to the results of the research study?

The final results from the study will be shared across relevant networks and will be made available on the RREAL website. We will aim to publish our findings in scientific journals and present them at national and international scientific meetings and conferences.

 

11. What happens if something goes wrong?

If you wish to complain or have any concerns about any aspect of the way you have been approached or treated through your participation in the research, you may wish to contact the researchers (details below).

 

12. Local Data Proctection Privacy Notice

The controller for this project will be University College London (UCL). The UCL Data Protection Officer provides oversight of UCL activities involving the processing of personal data, and can be contacted at data-protection@ucl.ac.uk. This ‘local’ privacy notice sets out the information that applies to this particular study. Further information on how UCL uses participant information can be found in our ‘general’ privacy notice.

The information that is required to be provided to participants under data protection legislation (GDPR and DPA 2018) is provided across both the ‘local’ and ‘general’ privacy notices. We will be collecting data on your country, type of institution and professional role. The lawful basis that will be used to process your personal data are: ‘Public task’ for personal data. Your personal data will be processed so long as it is required for the research project. If we are able to anonymise or pseudonymise the personal data you provide we will undertake this, and will endeavour to minimise the processing of personal data wherever possible.

If you are concerned about how your personal data is being processed, or if you would like to contact us about your rights, please contact UCL in the first instance at data-protection@ucl.ac.uk.

 

Researchers

Principal Investigator: Dr Pinkie Chambers (p.chambers@ucl.ac.uk)

Co-Investigator: Professor Ian Wong (i.wong@ucl.ac.uk)

Co-Investigator: Dr Cecilia Vindrola (c.vindrola@ucl.ac.uk)

If you have any questions or complaints, you can also contact the UCL Research Ethics Commitee (ethics@ucl.ac.uk).

 

Thank you for taking the time to read this information and for considering helping with our study. 

Participation is voluntary, clicking 'start' will be taken as consent.